Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Weiss

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
New anticancer agentsG R Weiss, C L Arteaga, T D Brown, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumorsG R Weiss, J G Kuhn, J Rizzo, et al.
Journal of the National Cancer Institute|January 16, 1991
Phase I clinical and pharmacokinetic trial of flavone acetic acidK A Havlin, J G Kuhn, J B Craig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Annals of Internal Medicine|April 1, 1988
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trialR I Fisher, C A Coltman, J H Doroshow, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Phase I and pharmacokinetic trial of weekly CPT-11M L Rothenberg, J G Kuhn, H A Burris, et al.
Gynecologic Oncology|January 15, 1999
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trialG R Weiss, P Y Liu, D S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Blood|March 21, 1998
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyureaG I Rodriguez, J G Kuhn, G R Weiss, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
New anticancer agentsG R Weiss, C L Arteaga, T D Brown, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumorsG R Weiss, J G Kuhn, J Rizzo, et al.
Journal of the National Cancer Institute|January 16, 1991
Phase I clinical and pharmacokinetic trial of flavone acetic acidK A Havlin, J G Kuhn, J B Craig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Annals of Internal Medicine|April 1, 1988
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trialR I Fisher, C A Coltman, J H Doroshow, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Phase I and pharmacokinetic trial of weekly CPT-11M L Rothenberg, J G Kuhn, H A Burris, et al.
Gynecologic Oncology|January 15, 1999
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trialG R Weiss, P Y Liu, D S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Blood|March 21, 1998
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyureaG I Rodriguez, J G Kuhn, G R Weiss, et al.
Pageof 10